Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells.

AIDS Res Hum Retroviruses. 1990 Aug;6(8):1011-5. Unique Identifier : AIDSLINE MED/91026264
Melder RJ; Balachandran R; Rinaldo CR; Gupta P; Whiteside TL; Herberman RB; Department of Pathology, University of Pittsburgh, PA 15213.

Abstract: Natural killer (NK) cells have long been known to aid in the control of viral infections by killing virus-infected cells, including those infected with human immunodeficiency virus (HIV). Among the possible NK-susceptible target cells in an infected individual, the monocyte/macrophages are of special significance since they may serve as both a reservoir of HIV and aid in dissemination of the virus throughout the body. A new technique for the enrichment and cultivation of large numbers of recombinant interleukin 2 (rIL-2)-stimulated NK cells has been developed which provides cells with high cytotoxic activity. These IL-2-activated NK cells, adherent lymphokine-activated killer cells (A-LAK), can kill monocytes infected with HIV for 24 h to 7 days, with optimal target sensitivity between 3 and 7 days. Recognition and killing of the infected monocytes did not appear to be restricted by the major histocompatibility complex (MHC) antigens and could be cold-target inhibited by tumor cell lines. A-LAK cells may be useful in newer therapeutic approaches to treatment of HIV infection.
Keywords: *Cytotoxicity, Immunologic Human HIV/*DRUG EFFECTS HIV Infections/*DRUG THERAPY/IMMUNOLOGY Interleukin-2/*PHARMACOLOGY Killer Cells, Natural/*IMMUNOLOGY Lymphocyte Transformation/*DRUG EFFECTS Monocytes/IMMUNOLOGY/*MICROBIOLOGY Recombinant Proteins/PHARMACOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Tumor Cells, Cultured JOURNAL ARTICLEKWDcytotoxicity,immunologichumanhiv/KWDdrugeffectshivinfections/KWDdrugtherapy/immunologyinterleukin-2/KWDpharmacologykillercells,natural/KWDimmunologylymphocytetransformation/KWDdrugeffectsmonocytes/immunology/KWDmicrobiologyrecombinantproteins/pharmacologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDtumorcells,culturedjournalarticle
910228
M9120688

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .